Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […]
More Stories
OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research report issued...
Pentair’s (PNR) Sector Weight Rating Reiterated at KeyCorp
KeyCorp restated their sector weight rating on shares of Pentair (NYSE:PNR – Free Report) in a research note issued to...
Citigroup Upgrades Veeco Instruments (NASDAQ:VECO) to “Buy”
Citigroup upgraded shares of Veeco Instruments (NASDAQ:VECO – Free Report) from a neutral rating to a buy rating in a...
Alliance Global Partners Reaffirms “Neutral” Rating for Canoo (NASDAQ:GOEV)
Alliance Global Partners reiterated their neutral rating on shares of Canoo (NASDAQ:GOEV – Free Report) in a research report report...
Nano-X Imaging (NASDAQ:NNOX) Research Coverage Started at D. Boral Capital
D. Boral Capital assumed coverage on shares of Nano-X Imaging (NASDAQ:NNOX – Free Report) in a report issued on Monday,...
AT&T (NYSE:T) Stock Rating Upgraded by Royal Bank of Canada
Royal Bank of Canada upgraded shares of AT&T (NYSE:T – Free Report) from a sector perform rating to an outperform...